XOMA Announces Presentations At Upcoming Investor Conferences

BERKELEY, Calif., March 1, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that company management will present at the following March conferences:

• RBC Capital Markets Healthcare Conference, March 3, 2011 at 11:00 a.m. Eastern time. Steven B. Engle, XOMA Chairman and Chief Executive Officer, will participate on a panel, "Antibody Therapeutics," chaired by Jason Kantor, Ph.D., Managing Director of RBC Capital Markets.
• Cowen & Company 31 ^st Annual Healthcare Conference, March 9, 2011 at 8:45 a.m. Eastern time. Fred Kurland, XOMA Vice President and Chief Financial Officer, will present a company overview.
• Roth Capital Partners Orange County Growth Stock Conference, March 15, 2011 at 8:00 a.m. Pacific time. Mr. Kurland will present a company overview.

Live webcasts of each presentation will be available via the Investors tab at the XOMA website, www.xoma.com . Archived versions of the webcasts will be available on the XOMA website for 30 days following each presentation.

About XOMA

XOMA discovers, develops and manufactures novel antibody therapeutics for its own proprietary pipeline as well as through license and collaborative agreements with pharmaceutical and biotechnology companies, and under its contracts with the U.S. government. The company's proprietary product pipeline includes:

• XOMA 052, a potent anti-IL-1 beta antibody entering Phase 3 clinical development in Behcet's uveitis, for which it has been designated an orphan drug, and in Phase 2 clinical development for Type 2 diabetes with cardiovascular biomarkers, Type 1 diabetes, and with potential for the treatment of a wide range of inflammatory conditions. XOMA is developing XOMA 052 in collaboration with Les Laboratoires Servier.
• XOMA 3AB, an antibody candidate in preclinical development to neutralize the botulinum toxin, among the most deadly potential bioterror threats, under development through funding provided by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
• A preclinical pipeline with candidates in development for autoimmune, cardio-metabolic, inflammatory, ophthalmic and oncologic diseases.

The company has a premier antibody discovery and development platform that incorporates an unmatched collection of antibody phage display libraries and proprietary Human Engineering™, affinity maturation, Bacterial Cell Expression (BCE) and manufacturing technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, 60 pharmaceutical and biotechnology companies have signed BCE licenses, and several licensed product candidates are in clinical development.